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The present dissertation focuses and expands on the optimization and application of poly(lacticco-glycolic acid) (PLGA)/polyvinyl alcohol (PVA) composite coatings and initiates metabolic
studies in small animals to identify novel biomarkers to be utilized in exhaustion prediction. The
composites are used to coat implantable biosensors and improve their biocompatibility. The
objectives of the work are: i) investigate species differences related to the foreign body reaction
(FBR) between small and large animals; ii) develop composite coatings to prevent the FBR in
large animals; iii) develop composites loaded with combinations of dexamethasone, vascular
endothelial growth factor (VEGF) and platelet derived growth factor (PDGF) to promote
angiogenesis around implanted biosensors; and iv) apply multi-analyte monitoring to exhaustion
prediction.
The onset and severity of fibrosis was identified as a key difference between minipigs and rats,
with minipigs demonstrating earlier onset and more severe chronic inflammation. In order to
counter this, dexamethasone release must be continuous, with no lag phase. The effective
dexamethasone dosing regime was 100 μg during the first day and 10 μg/day thereafter.
A novel method for the preparation of microspheres containing insoluble drugs was developed to
achieve homogeneous drug distribution, high loading and low burst release. Dexamethasone
microspheres prepared by this method were utilized in microsphere/hydrogel composite coatings
which successfully prevented FBR in a large animal model for a period of one month.
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Combinations of dexamethasone, VEGF and PDGF were investigated for the first time to prevent
FBR and promote angiogenesis. It was determined that VEGF has to be delivered at higher doses
than PDGF and an increase in dexamethasone must be accompanied by proportional increase in
growth factors.
An array of biomarkers that can be used in exhaustion prediction was successfully identified, with
prediction times ranging from 10 to 20 minutes in normal as well as type 1 diabetic rats. It was
discovered that multi-analyte biomarkers based on glucose and lactate are far more responsive in
the subcutaneous tissue (an implantation-friendly compartment) than in the blood.
In conclusion, the outcomes of this work contribute to the advancement biomaterials, as well as
applications in exercise physiology.
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Figure 2.1.

Histological evaluation of the foreign body reaction to control (no
dexamethasone) implants. Star denotes implant location. Connective
tissue is stained pink, collagen fibers light pink and inflammatory cells
purple (H&E staining). a: day 1; b: day 3; c: day 7; d: day 14; e: day 21;
f: day 30 post-implantation (n=3). Scale bar: 500 μm.
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Figure 2.2.

Comparison of FBR in rats and minipigs 7 days post-implantation. Star
denotes implant location. Connective tissue is stained pink, collagen
fibers light pink and inflammatory cells purple (H&E staining). Green
arrow: collagen fibers; black arrow: fibroblasts. Rat image taken from
Patil et. al.43 Fibroblasts were identified based on the cell morphology.
Active fibroblasts have oval shape with spherical nucleus and are
characteristically positioned in-between collagen fibers which they
produce.
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Figure 2.3.

Histological evaluation of the foreign body reaction to dexamethasonereleasing implants R, R9, R11 and R150 on days 3, 7, 14, 21, and 30
post-implantation. Star denotes implant location. Connective tissue is
stained pink, collagen fibers light pink and inflammatory cells purple
(H&E staining) (n=3). Scale bar: 500 μm.
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Figure 2.4.

Histological evaluation of the foreign body reaction to dexamethasonereleasing implants R2W. Star denotes implant location. Connective
tissue is stained pink, collagen fibers light pink and inflammatory cells
purple (H&E staining). a: day 1; b: day 3; c: day 7; d: day 11; e: day 14;
f: day 21 post-implantation (n=4). Scale bar: 500 μm.
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Figure 3.1.

Polarized light microscopy (PLM) images of two emulsions during
PLGA microsphere preparation. Drug crystals appear as bright spots in
the PLM images. (a) Example of non-optimized process, with
dexamethasone crystals formed outside the polymer phase (polymer
droplets not visible due to their inability to polarize light). (b)
Optimized formulation with dexamethasone precipitated inside the
polymer phase. Magnification: 10X, scale bar: 500 μm.
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Figure 3.2.

PLM images of negative control formulation (left) with poor drug
distribution in the polymer matrix and optimized formulation (right).
Dexamethasone crystals appear bright under PLM while the polymer is
transparent. Magnification: 40X, scale bars: 10 μm.
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Figure 3.3.

Cumulative in vitro release of dexamethasone from optimized PLGA
microspheres embedded in a PVA hydrogels. All values are average ±
SD (n = 3). Linear regression was applied from day 4 to day 45.
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Figure 3.4.

Histological evaluation of the foreign body reaction to control (no
dexamethasone) implants. Star denotes implant location. Connective
tissue is stained pink, collagen fibers light pink and inflammatory cells
purple (H&E staining). (a) day 3; (b) day 7; (c) day 14; (d) day 21; (e)
day 30 post-implantation. Magnification: 10X, scale bar: 500 μm.
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vii

Figure 3.5.

Histological evaluation of the foreign body reaction to coated silicon
chips with the optimized PLGA microsphere formulation. Star denotes
implant location. Connective tissue is stained pink, collagen fibers light
pink and inflammatory cells purple (H&E staining). (a) day 3; (b) day
7; (c) day 14; (d) day 21; (e) day 30 post-implantation. Magnification:
10X, scale bar: 500 μm.
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Figure 3.6.

Histological evaluation of FBR to composites with the optimized
PLGA microsphere formulation with no silicon chips at their core. Star
denotes implant location. Connective tissue is stained pink, collagen
fibers light pink and inflammatory cells purple (H&E staining). (a) day
3; (b) day 7; (c) day 14; (d) day 21; (e) day 30 post-implantation.
Magnification: 10X, scale bar: 500 μm.
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Figure 4.1.

Schematic representation of the single-vessel microsphere preparation
process.
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Figure 4.2.

a) Confocal microscopy images of protein microsphere formulations
with (right) and without (left) NaCl in the outer water phase; b) drug
loading, encapsulation efficiency, and % burst release of the
formulations with and without NaCl (mean ± SD, n=3).
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Figure 4.3.

Anti-sma-stained tissue sections showing normal tissue (N) and
composites C, D, DV, DVP, and D2VPa. Star denotes implant location.
Magnification: 20x. Scale bar: 150 μm.
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Figure 4.4.

H&E-stained tissue sections of composites D, DV, D2VPb, and 2D2VP
at different time points following implantation. Star denotes implant
location. Magnification: 10x. Scale bar: 500 μm.
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Figure 4.5.

Anti-sma-stained tissue sections of composites D, DV, D2VPb, and
2D2VP at different time points following implantation. Star denotes
implant location. Magnification: 10x. Scale bar: 500 μm.
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Figure 4.6.

Anti-sma-stained tissue sections of composites D, DV, D2VPb, and
2D2VP at different time points following implantation. Star denotes
implant location. Magnification: 140x. Scale bar: 100 μm.
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Figure 4.7.

Capillary density within a 200 μm distance from the implant surface for
composites D, DV, D2VPb and 2D2VP (mean ± SD, n=3).
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Figure 5.1.

Effect of light and intense exercise on oxygen and carbon dioxide levels
in the blood and subcutaneous tissue. Areas shaded blue and green
indicate light and intense exercise, respectively, and unshaded areas
indicate periods of inactivity (rest or recovery). The top panel displays
oxygen level changes and the bottom panel carbon dioxide changes in
the dialysate. Arrows indicate y axis. Oxygen levels did not respond to
light exercise but only during intense exercise. Carbon dioxide levels
responded to both light and intense exercise, but showed highly
unstable readings.
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viii

Figure 5.2.

Effect of intense exercise and exhaustion on glucose and lactate levels
in the blood and subcutaneous tissue. Areas shaded green and red
indicate periods of intense exercise and exhaustion, respectively.
Exhaustion was defined as the time when the animal could not keep up
with the exercise and the running speed needed to be adjusted.
Unshaded areas indicate periods of inactivity (rest or recovery). Arrows
indicate y axis. Top panels show glucose and lower panels show lactate
changes in the dialysate. Panel a shows representative graph from a
normal rat and panel b from a diabetic rat. Changes in analyte trends
precede the onset of exhaustion (red ovals). These are clearer in lactate
trends for both normal and diabetic rats.
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Figure 5.3.

Slope changes for various biomarker combinations of glucose (GLU)
and lactate (LAC). All ratios are molar and the percentile changes are
calculated based on the baseline measurements before the
commencement of the exercise. The first peak represents metabolic
changes from rest to activity and the second peak metabolic changes
that precede exhaustion (predictive). Panel a shows representative
results from a normal rat and panel b from a diabetic rat.

87

Figure 5.4a.

Effect of intense exercise and exhaustion on the biomarker 2LAC/GLU
(molar ratio of lactate and glucose multiplied by 2). Areas shaded green
and red indicate periods of intense exercise and exhaustion,
respectively. Exhaustion was defined as the time when the animal could
not keep up with the exercise and the running speed needed to be
adjusted. Unshaded areas indicate periods of inactivity (rest or
recovery). Arrows indicate y axis. Red ovals indicate the exhaustionprediction point. The top panel shows representative results from a
normal rat and the bottom panel from a diabetic rat. 2LAC/GLU is the
optimum biomarker for detecting metabolic changes in the
subcutaneous tissue predictive of imminent exhaustion. The results are
less clear in the diabetic rat; please note that diabetic rats did not receive
insulin treatment, and the baseline glucose was high. This likely
interfered with the biomarkers.

88

Figure 5.4b.

3D representation of glucose and lactate changes during intense
exercise and exhaustion in a normal rat. This plot reveals the
interdependence of glucose and lactate that can be extrapolated to
evaluate the metabolic flexibility (the ability to transition from aerobic
to anaerobic energy utilization). The peak in the graph indicates
metabolic changes predictive of exhaustion.
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Table 2.1.

Appendix II - Tables
Implant composition and size.
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Table 2.2

Physical properties of PLGA microspheres. Results are average values
± SD (n=3).
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Table 4.1.

Microsphere content in the composites
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Chapter 1
Introduction

1

1.1. Background
Diabetes mellitus1-3, obesity4-9, metabolic syndrome8, 10-15 and intense physical activity16-19 are
a few examples of conditions whose management requires close monitoring of their progress and
status. Typically, this takes place via monitoring of the overall physical condition of the individual
(weight, weight fluctuations, routine blood/urine tests, etc.). In addition to routine health screening,
monitoring of condition-specific biomarkers is essential for adequate management as well as
prevention in high-risk populations. For example, blood pressure and lipid content are periodically
checked in patients with metabolic syndrome or those at risk of developing metabolic syndrome
such as the obese.
Glucose, the main energy source in the body, has been identified as one of the most informative
metabolic biomarkers regardless of the metabolic condition being treated. Fasting glucose20-24 and
the oral glucose tolerance test (OGTT)25-30 are two tests run routinely (typically on a semi-annual
or quarterly basis) to pick up metabolic abnormalities. Diabetic patients require more frequent
glucose monitoring (multi-daily) in order to account for pre-meal blood glucose concentrations
when deciding the dose of insulin to be injected and/or the type and amount of food to be
consumed. However, the aforementioned glucose tests and monitoring regimes can only give
discreet values of glucose levels; they do not provide glucose trends (increasing or decreasing) or
glucose fluctuations between measurements. As a result, managing the metabolic condition
becomes a daily struggle for patients who are required to be on alert 24/7 and take important
decisions on insulin (a very toxic drug) dosing. Accordingly, continuous glucose monitoring is
necessary for the successful management of metabolic diseases, particularly diabetes.
Previous research has provided competitive solutions towards the realization of a fully
implantable metabolic biosensor regarding the four major challenges surrounding metabolic
2

monitoring: i) long-term biosensor functionality in the body; ii) sensitivity and response linearity
of multi-analyte biosensors; iii) miniaturization and wireless communications; and iv)
interpretation of metabolic data and identification of monitoring biomarkers. This has resulted in:
a) subcutaneously-implanted multi-analyte biosensors with superior sensitivity and response
linearity in rats31, 32; b) miniaturized electrical circuits and wireless communication and power
supply platforms33; and c) composite biosensor coatings that suppress the body’s reaction to
implanted biosensors for three months in rats34-38.
The biosensor coatings presented here are made of poly(lactic-co-glycolic acid) (PLGA)
microspheres embedded in a polyvinyl alcohol (PVA) hydrogel. The PVA hydrogel acts as base
for the coating that allows glucose and other analytes to diffuse from the local microenvironment
to the biosensor. In addition, PVA-based hydrogels have mechanical properties similar to that of
soft tissues such as the subcutaneous tissue; this ensures that the implant will not cause tissue
trauma. The PLGA microspheres serve as drug depots that release dexamethasone, a synthetic
glucocorticosteroid with immunosuppressant and anti-inflammatory action. Dexamethasone was
chosen due to its high potency that allows suppression of the foreign body response (FBR) with
small amounts of drug, a necessity resulting from the small size of the biosensors. The PLGA
microsphere/PVA hydrogel coatings have been tested in small animals (rats) to optimize the
dexamethasone dose and release kinetics. Our group has successfully tested a first generation of
semi-implantable coated glucose biosensors in rats that maintained functionality for one month.
In addition to dexamethasone, vascular endothelial growth factor (VEGF) has been
incorporated in the PLGA/PVA coatings to induce angiogenesis, the sprouting of blood vessels39.
Continuous release of VEGF from the PLGA microspheres into the subcutaneous tissue
microenvironment has offset the dexamethasone-induced ischemia observed in dexamethasone3

only coatings. Adequate perfusion (amount of blood volume) at the biosensor microenvironment
is essential to ensure rapid transfer of blood glucose to the subcutaneous tissue, to be quantified
by the implanted biosensor with minimal lag time.
1.2. Objectives
The present dissertation focuses and expands on the optimization and application of
poly(lactic-co-glycolic acid) (PLGA)/polyvinyl alcohol (PVA) composite coatings and initiates
metabolic studies in small animals to identify novel biomarkers to be utilized in exhaustion
prediction. These composites are used to coat implantable biosensors and improve their
biocompatibility. The objectives of the work are: i) investigate species differences related to the
foreign body reaction (FBR) between small and large animals; ii) develop composite coatings to
prevent the FBR in large animals; iii) develop composites loaded with combinations of
dexamethasone, vascular endothelial growth factor (VEGF) and platelet derived growth factor
(PDGF) to promote angiogenesis around implanted biosensors; and iv) apply multi-analyte
monitoring for exhaustion prediction.
The work was divided into four Specific Aims:
SA-I

Prevention of the foreign body reaction in a pre-clinical large animal model: inter-species

differences
SA-II Development of dexamethasone-loaded PLGA microspheres for long-term prevention of
the foreign body reaction in Gottingen minipigs
SA-III Delivery of dexamethasone, VEGF, and PDGF to promote angiogenesis and prevent the
foreign body reaction in subcutaneous implants
SA-IV Continuous metabolic monitoring based on multi-analyte biomarkers to predict exhaustion
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Chapter 2
Prevention of Foreign Body Reaction in a Pre-Clinical Large Animal Model
Abstract
In this work, the foreign body reaction (FBR) to small subcutaneous implants was compared
between small (rodent) and large (swine) animal species for the first time. Dexamethasonereleasing poly(lactic-co-glycolic acid) microspheres/polyvinyl alcohol hydrogel composite
coatings were adapted to prevent FBR to small, subcutaneous implants in a large animal model
(Goettingen minipigs). The implants consisted of small silicon chips (used to mimic small medical
devices) that were coated with the composite formulations. The stages of the FBR were compared
with previous studies in rats (that used the same-sized implants); the onset and severity of chronic
inflammation (collagen deposition) was identified as a key difference between the two species. In
the absence of inflammation control, fibrosis was observed from day 7 post-implantation in
minipigs, whereas in rats this did not occur until day 14. This is significant as swine skin is the
most commonly used model for preclinical testing of dermal formulations. It was determined that
for long-term prevention of the FBR (longer than 24 hours), a lag phase in dexamethasone release
between days 1 and 10 did not affect the anti-FBR properties of the implant in rats. However,
continuous release of dexamethasone, with no lag phase, was necessary to prevent inflammation
in minipigs (effective dexamethasone dose was 100 μg delivered immediately after implantation
and 10 μg/day delivered continuously thereafter). This study offers significant insight into the
translation of anti-FBR strategies across species, and showcases the importance of tailoring the
controlled release kinetics of the formulation to the host response.
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2.1. Introduction
Implantable biomaterials such as biosensors are recognized by the immune system as foreign;
this leads to a cascade of events collectively known as the foreign body reaction (FBR) 1, 2. The
FBR consists of two main phases: an acute phase, characterized by the infiltration of inflammatory
cells, mainly neutrophils, and a chronic phase, characterized by the presence of active fibroblasts
(cells that deposit collagen fibers around the implant)1, 3-5. The collagen fibers will ultimately
encapsulate the foreign body in a dense, fibrous collagen layer (fibrosis).
The FBR has been the focus of many research studies over the past decades. Most of the early
work in this area was related to organ rejection prevention6-8. In recent years, the emergence of
implantable medical devices has led to the FBR being investigated to extend device lifetime9-12. In
the case of subcutaneously implanted devices, their size, shape, mechanical properties, type of
biomaterial, implantation duration and even method of implantation can yield a different response.
The FBR can be minimized by using materials with mechanical properties similar to those of the
surrounding tissue13-15, by incorporating hydrophilic coatings that prevent protein adsorption
(biofouling)16-20 and by using biocompatible materials that do not produce toxic or irritating byproducts upon degradation21-24. However, these approaches only minimize the FBR but do not
eliminate it altogether. The only method that has been shown to completely prevent the FBR is the
use of local delivery of anti-inflammatory agents which prevent infiltration and further attraction
of inflammatory cells25-32. Systemic administration of anti-inflammatory agents and immunosuppressants is regularly used to prevent organ rejection33-41 but it is not a desirable approach for
medical devices and implantable biomaterials due to the high risk-to-benefit ratio.
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Dexamethasone, a synthetic glucocorticoid, is the most commonly used anti-inflammatory
agent to prevent FBR26, 27, 29, 31. Due to its potency, only small amounts of dexamethasone are
required; this is essential for small implants where space is limited. Implant coatings designed to
suppress the FBR for implantable glucose biosensors have been previously reported and their
efficacy has been tested in several rat models (normal, diabetic, and obese) for one and three month
implantation durations9, 11,

28, 42-46

. Dexamethasone was delivered throughout the implantation

period by incorporation in poly(lactic-co-glycolic acid) (PLGA) microspheres that were embedded
in a polyvinyl alcohol (PVA) hydrogel coating. While studying the efficacy of these coatings in
small animals is necessary as proof-of-concept, it is accepted that studies in larger animals are
required in order to extrapolate the results to design the first-in-human clinical trials. The
Goettingen minipig, a breed of miniature swine, is a common animal model for dermal studies due
to the similarities between human and swine skin47-50. The objective of the present work was to
study the FBR to miniaturized implantable biomaterials in the Goettingen minipig, identify key
parameters that will determine anti-FBR dosing regimens of dexamethasone, and apply the
findings for long-term prevention of the FBR. To achieve this, PLGA microsphere/PVA hydrogel
composites that release dexamethasone in various amounts and rates (as determined in previously
published work from our group51) were prepared. The composites were used to coat silicon chips,
mimicking an implantable biosensor, and were implanted in the subcutaneous tissue of Goettingen
minipigs. The local tissue reaction to the implants was determined histologically at multiple time
points after implantation.
2.2. Materials and Methods
2.2.1. Materials
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Dexamethasone was purchased from Cayman Chemical Company (Ann Arbor, MI). Highmolecular weight poly(vinyl alcohol) (HMW-PVA, MW 30–70 kDa), was purchased from
Polysciences, Inc. (Warrington, PA) and low-molecular weight PVA (LMW-PVA, 99 %
hydrolyzed, MW 133 kDa) was purchased from Sigma-Aldrich (St. Louis, MO). PLGA Resomer®
RG503H (inherent viscosity 0.32–0.44 dl/g) was a gift from Boehringer-Ingelheim and PLGA
DLG2A (inherent viscosity 0.15–0.25 dl/g), was a gift from SurModics Pharmaceuticals
(Birmingham, AL). Methylene chloride and dimethyl sulfoxide (DMSO, ACS grade) were
purchased from Fisher Scientific (Pittsburghm, PA).
2.2.2. PLGA microsphere preparation.
Dexamethasone-loaded PLGA microspheres were prepared as previously described9. Briefly,
2 g of PLGA were dissolved in 8 ml methylene chloride (DCM). 200 mg of crystalline
dexamethasone were added to the polymer solution and the mixture was homogenized at 10,000
rpm for 2.5 min using a T 25 digital ULTRA-TURRAX® homogenizer (IKA® Works, Inc.) to
obtain a homogenous suspension. The suspension was subsequently transferred to 40 ml of 1%
w/v LMW-PVA aqueous solution and homogenized for 1 min at 10,000 rpm to obtain a solid-oilwater emulsion. The emulsion was transferred to 500 ml of 0.1% w/v LMW-PVA aqueous solution
and stirred at 600 rpm under vacuum for 3 hours to remove the DCM. The hardened microspheres
were purified via three centrifugation cycles at 3,500 rpm for 2 min each, freeze dried and stored
at 4 oC until further use. Blank microspheres were prepared in the same way without the addition
of dexamethasone. PLGA polymers of two molecular weights were used in different preparations:
25,000 g/mol (50:50 Resomer 503H) and 12,000 g/mol (50:50 DLG 2A).
2.2.3. Preparation of implants
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Implants were of cylindrical shape and consisted of a rectangular silicon chip core (5x0.5x0.5
mm) coated with PVA hydrogel embedded with PLGA microspheres (7-11 mm length, 1.5 mm
diameter when hydrated). To coat the silicon chips, 75 or 150 mg of microspheres were suspended
in 1 ml of 5% w/v HMW-PVA aqueous solution. The mixture was vortexed and placed in a
sonicated bath for 10 seconds to achieve good microsphere distribution and break any aggregates.
The PVA hydrogel was formed after physical crosslinking of the HMW-PVA via three freeze thaw
cycles. First, the suspension was subjected to one freeze-thaw cycle (2 h at -20 oC and 1 h at
ambient temperature). After the first cycle, the partially thickened suspension was fed in a twopiece grooved mold (grooves of 1.5 mm in diameter). The silicon chips were sandwiched between
the two mold pieces that were then subjected to two more freeze-thaw cycles to complete the PVA
crosslinking and form a self-supporting hydrogel around the chips. Each mold was used to coat 30
silicon chips of approximately 2 mg weight. Please note that low-molecular weight PVA was used
as a surfactant to improve emulsion stability during the microsphere preparation process, while
high-molecular weight PVA was used to form a hydrogel. Hydrogel strips containing the silicon
chips were air-dried and cut at 7, 9 or 11 mm length implants. The implants were placed in 16
gauge needles and stored at 4 oC until further use. Different implant formulations were labeled as
shown in Table 2.1.
2.2.4. PLGA microsphere characterization
Particle size: An Accusizer 780 (Particle Sizing Systems) was used to measure the particle size
of the PLGA microspheres. 3-5 mg of dried microspheres were suspended in 1 ml of 0.1% w/v
LMW-PVA solution, bath-sonicated for 10 s and analyzed for volume-based average size.
Dexamethasone loading: 5 mg of dried microspheres or composites were dissolved in 1 ml
DMSO and then diluted 10 times in phosphate buffered saline (PBS) pH 7.4. Dexamethasone
12

concentration

was

determined

via

RP-HPLC

(PerkinElmer,

Inc.).

Mobile

phase:

acetonitrile/water/phosphoric acid (30/70/0.5%, v/v/v); column: Zorbax® C18 (4.6 mm×15 cm);
detection wavelength: 240 nm; flow rate: 1 ml/min.
2.2.5. In vivo pharmacodynamics study
Seven young, female Goettingen minipigs were used as a large animal model to study the
inhibition of the FBR to subcutaneous implants. Minipigs were studied in iterations of 2 or 3
animals. The number of animals that were utilized for each formulation is indicated in the figure
legends. Each study lasted for 30 days. The implants that were tested are shown in Table 2.1. They
were implanted at the back of the animals on days 0, 9, 16, 23, 27, and 29. All implants were
spaced at least 5 cm apart to ensure no interference. The area right above the spinal cord was not
implanted. The animals were sacrificed on day 30 and the implants with surrounding subcutaneous
tissue were harvested and stored in 10% buffered formalin solution (Sigma-Aldrich Co. LLC.).
This resulted in implants being excised on days 1, 3, 7, 14, 21, and 30 post-implantation. All time
points were ± 3 days to allow for unforeseeable delays. The extracted implants that prevented the
FBR were analyzed for the remaining dexamethasone content. All animal studies were reviewed
and approved by the University of Connecticut’s Institutional Animal Care and Use Committee
(IACUC) prior to the beginning of the experiments.
2.2.6. Histological evaluation
Fixed tissues were processed, embedded in paraffin and sectioned in 20 μm films at the
University of Connecticut’s Pathobiology Department. Tissue sections were stained with
Hematoxylin & Eosin (H&E) and the presence and progress of the FBR was evaluated by
observation under a light microscope. Normal connective tissue appears pink, adipose tissue white,
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deposited collagen fibers light pink, and inflammatory cells purple. Digital images representative
of the tissue reaction around the implants are presented here.
2.3. Results
2.3.1. Microsphere characterization
Physical properties of the microspheres were measured to confirm that the formulations were
consistent with the previous work51. The particle size and drug loading of the microspheres are
shown in Table 2.2. Please note that due to the low solubility of dexamethasone in water and some
polymer loss during microsphere preparation, the dexamethasone loading exceeded the theoretical
(10% by weight).
2.3.2. FBR to implants with no dexamethasone
Implants coated with blank (no dexamethasone) microspheres embedded in PVA hydrogel
were used to study the FBR in Goettingen minipigs. Tissue sections excised at 3, 7, 14, 21 and 30
days after implantation give a representation of the progress of the FBR (Figure 2.1).
The FBR consisted of the typical acute phase observed on day 3 (indicated by the presence of
purple-stained inflammatory cells around the implant), and the chronic phase with fibrous
encapsulation clearly visible from day 14 onwards (observed as a light pink band with collagen
fibers oriented around the implant). Collagen deposition around the implant can be clearly seen on
day 7 prior to fibrous encapsulation (Figure 2.2).
2.3.3. Effect of total dexamethasone dose
Implants coated with dexamethasone-loaded composites were used to determine whether the
formulation that was effective in normal, diabetic and obese rats can be used in large animals.
Implant R was the reference formulation which had the same composition as that which was
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effective in all rat models9. Implants with higher dexamethasone doses were also tested in order
to optimize the dexamethasone dosing. Two strategies to increase the total dexamethasone per
implant were employed: a) doubling the microsphere density in the coating to 150 mg per 1 ml of
PVA hydrogel (the maximum microsphere content that allows enough glucose permeability
through the implant as determined in previous studies, unpublished data by Burgess et. al.); and
b) increasing the implant length from 7 to 11 mm. All implant preparations are detailed in Table
2.1.
As shown in Figure 2.3, the implants with the higher dexamethasone doses (implants R150 and
R11) completely suppressed the acute inflammation as no cell infiltration was observed on day 3
post-implantation. Implants R and R9 with lower dexamethasone doses, including the reference
implant, did not completely prevent the acute inflammatory phase but did reduce it significantly
compared to the control. However, none of the implants prevented the chronic phase of the FBR,
and collagen deposition is observed from day 7 in all cases, with the fibrous capsule being observed
from day 14. The implants with the higher dexamethasone doses (implants R150 and R11) showed
relatively less dense fibrous capsules compared to the control implants, however, this is not
satisfactory for the purpose of long-term prevention of FBR to prolong the functionality of
implantable biomaterials.
2.3.4. Effect of PLGA molecular weight
Implants made with PLGA microspheres of lower molecular weight were tested. These
microspheres release dexamethasone continuously for two weeks, with no lag phase, as previously
reported51. A formulation with lower molecular weight PLGA microspheres loaded in PVA
hydrogels with the maximum amount (150 mg per 1 ml hydrogel) was tested (implant R2W). As
shown in Figure 2.4 this formulation prevented acute inflammation (no inflammatory cell
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accumulation, pane A in Figure 2.4) as well as chronic inflammation (no fibrous encapsulation,
panel D in Figure 2.4) up to day 11. Minimal collagen deposition was observed on day 14 when
dexamethasone was depleted. Implants extracted 1 and 14 days after implantation were analyzed
for dexamethasone content. It was determined that after 24 hours, 61.56 ± 5.72 % of
dexamethasone remained in the implant (i.e. 35.16 ± 5.72 % released during the burst phase) while
7.77 ± 1.82 % remained in the implant at the end of 14 days (i.e. 92.81 ± 1.82 % released).
Accordingly, the effective dexamethasone dose was calculated based on 40% of the total
dexamethasone released during the first 24 hours and the rest continuously released throughout the
implantation period (approximately 100 μg released the first day and 10 μg/day throughout the
remainder of the implantation period).
2.4. Discussion
Local delivery of dexamethasone, an anti-inflammatory agent, has been successfully used to
counter the FBR to subcutaneously-implanted biomaterials in normal, obese and diabetic rats. In
order to translate this technology to the clinic, it was decided to bridge the gap between rats and
humans by using a large animal model, Goettingen minipigs. The progress and prevention of the
FBR was studied, with the intention to directly compare the finding with corresponding
investigations in rats. Direct comparison was made possible by starting with implants with the
same characteristics as the ones that were previously tested in rats (size, shape, mechanical
properties, materials, anti-inflammatory drug)9. Our results reveal critical factors that need to be
taken into consideration when extrapolating this type of data across different species.
It was found that while the events leading to fibrotic encapsulation are similar between
minipigs and rats, their timing differs significantly. In rats, fibroblast recruitment and activation
starts 14 days after implantation42, while in minipigs active fibroblasts and collagen deposition can
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be observed from day 7. This is shown in Figure 2.1 panel c and in Figure 2.2 where a dense
collagen network surrounds the implant. This network will later on contract to form the fibrotic
membrane isolating the implant. In the corresponding studies in rats, no dense collagen network
was observed on day 7 after implantation. Instead, loose connective tissue similar to subcutaneous
tissue under normal conditions was observed. The difference in the onset of fibrosis between rats
and minipigs is of great importance as it indicates a difference in the severity of the chronic
inflammation between the two species and consequently the amount of drug necessary to counter
it.
In transition from small to large animals during preclinical testing of drug-releasing
formulations, dose is usually scaled up according to body weight with corrections based on
empirical formulas. In the case of locally-acting implants, however, dose scale-up is not necessary
as no systemic effect is desired. In order to prevent the FBR to devices implanted in the
subcutaneous tissue, a minimum level of drug has to be maintained in the local environment
throughout the implantation period. This level may vary from species to species due to differences
in drug clearance from the subcutaneous tissue, drug diffusion rates through the tissue, drug
metabolism and the presence of cells.
Implants made of PLGA microspheres of the same molecular weight as the ones tested in rats
and same total dexamethasone loading were used as reference formulations. These implants did
not prevent the FBR and the tissue surrounding them was similar to that around the control
implants. As evidenced by the absence of inflammatory cell accumulation in Figure 2.3, higher
dexamethasone doses prevented the acute phase of the FBR. The higher dexamethasone doses
were achieved by either increasing the microsphere density in the biocompatible coating or
increasing the total length of the implants. However, increasing the dexamethasone dose was
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limited due to the small size of the implants. The maximum amount of dexamethasone per implant
that was achieved was 0.22 mg. This amount was not enough to prevent fibrous encapsulation of
the implants.
Based on the in vitro dissolution testing of these implants51, 40% of the drug is released within
the first 24 hours and the remaining amount is released continuously starting from about day 10
post-implantation. This leaves a nine-day period with little-to-no dexamethasone release in the
tissue (lag phase). The lag phase did not interfere with the anti-FBR effect of the implants in rats.
Based on the observations on the earlier timing of fibrosis onset in minipigs compared to rats, it
was hypothesized that eliminating this lag phase might prevent FBR. This hypothesis was tested
and confirmed using PLGA microspheres of a lower molecular weight. Implants made with these
microspheres release dexamethasone continuously for about 14 days with no lag phase51. Once
implanted in the minipigs, the implants prevented the FBR until day 11 and early collagen
deposition is observed on day 14. This is likely due to the dexamethasone depletion that occurs
around that time.
Based on the results discussed above, the dexamethasone dose that is effective to counter the
FBR in Goettingen minipigs is ~100 μg released during the first day (to counter the acute
inflammation cause by tissue trauma) and about 10 μg/day released continuously throughout the
implantation period (to prevent fibroblast activation and collagen deposition). This was confirmed
following analysis of the amount of dexamethasone remaining in exctracted implants at 24 hours
and 14 days. This dosing regimen applies to subcutaneously-implanted materials of small size
(around 7x1.5 mm when hydrated). It has been previously shown that the size of the implant affects
the severity of the FBR in rats, so dose adjustment will likely be necessary for implants of different
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sizes. The release kinetics of dexamethasone, however, will have to remain the same, i.e. a burst
release followed by a continuous, zero-order release throughout the implantation period.
The size of our implants was chosen to reflect the trend of miniaturization of implantable
medical devices. The extent of the anti-inflammatory drug dose limitation varies from implant to
implant and it depends on implant size, desired coating thickness, desired coating permeability to
various tissue molecules, and the type of controlled release vesicle used to deliver the drug. In
order to extend the anti-FBR effect of the biomaterials beyond the two-week period achieved here,
the drug-carrier technology (in this case the PLGA microspheres) has to be optimized or replaced
in order to maximize the drug loading efficiency and accommodate high dexamethasone doses in
such small samples.
2.5. Conclusions
In the present work, the FBR to subcutaneous implants was compared between a small and
large animal model for the first time. The onset and severity of fibrosis was identified as a key
difference with minipigs, demonstrating earlier onset and more severe chronic inflammation
compared to rats. It was determined that the dexamethasone release from the implant coatings must
be tailored to the species-specific stages of the FBR. In order to counter the more severe chronic
inflammation observed in minipigs compared to rats, dexamethasone release must be continuous,
with no lag phase. The effective dexamethasone dosing regime was 100 μg during the first day
and 10 μg/day thereafter; this regime is applicable to implants of similar size (7 x 0.15 mm) and
can be extrapolated to longer implantation periods in minipigs. Lastly, these findings can facilitate
the dose calculations in the first-in-human studies as porcine skin is the optimal model for dermal
formulations.
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Chapter 3
Development of Dexamethasone-Loaded PLGA Microspheres for Long-Term
Prevention of the Foreign Body Reaction in Gottingen Minipigs
Abstract
An important strategy currently used to prevent the foreign body reaction (FBR) to subcutaneous
implants in animal models is the constant release of dexamethasone in the tissue surrounding the
implant. There have been few studies in large animal models including: 1) a bulky osmotic pump
system that delivers dexamethasone over a one-month period; and 2) a poly(lactic-co-glycolic
acid) (PLGA) microsphere/polyvinyl alcohol (PVA) hydrogel composite coating for miniaturized
implants that locally delivers dexamethasone for a two-week period in minipigs. A long-term
strategy to prevent FBR to subcutaneous implants in a large animal model is necessary. In this
work, a PLGA microsphere/PVA hydrogel composite coating for the one-month prevention of the
FBR in Gottingen minipigs was developed. This coating is suitable for miniaturized implantable
devices (of a few mm length), such as biosensors, that require constant communication with the
local microenvironment to function. The microspheres were prepared via dexamethasone/polymer
co-precipitation which resulted homogeneous distribution of dexamethasone in the microsphere
matrix which in turn gave rise to increased drug loading, low burst release, and minimal lag phase.
The in vivo functionality of the composite coatings was evaluated via histological examination of
explanted tissue samples from the area surrounding the implants.
Keywords: PLGA microspheres; dexamethasone; foreign body reaction; swine; co-precipitation.
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3.1. Introduction
Once implanted, biomaterials face the host tissue’s response (foreign body reaction, FBR)
which often interferes with their intended action1-8. The final result of the FBR is isolation of the
implant from the surrounding tissue via fibrous encapsulation9-11. This can inhibit drug transport
in the case of drug-delivering biomaterials, prevents healing in the case of tissue engineering
scaffolds, and stops analyte diffusion in the case of implantable biosensors. The effect of, as well
as the prevention of FBR for various types of biomaterials has been studied using different animal
models11-14.
The FBR consists of a cascade of events that includes, among others, inflammatory cell
recruitment, collagen deposition, and formation of an avascular fibrotic capsule around the foreign
body. Most of these steps are preserved across different species, however, some differences exist.
It has been reported that diabetic rats lack the high levels of mast cells that are observed in normal
rat subcutaneous tissue during the FBR15. The function of mast cells is to exacerbate acute
inflammation and as a result diabetic rats show a less severe response in the days immediately
following implantation. Other parts of the FBR have been compared between different species,
such as nitric oxide production from human, mouse and rat macrophages16 and the presence of
basophilic granules in humans and pigs17, 18.
Our

group

has

previously

developed

poly(lactic-co-glycolic

acid)

(PLGA)

microsphere/polyvinyl alcohol (PVA) hydrogel-based composites capable of preventing the FBR
to subcutaneously-implanted materials15, 19-24. This is achieved via delivery of dexamethasone, a
synthetic corticosteroid with potent anti-inflammatory properties. The dexamethasone dose and
release kinetics have been optimized for up to a three-month implantation period19 in rat models
(normal, type 1 diabetic, obese15) as well as in a large animal model (Gottingen minipigs) for a
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two-week implantation period. Ward et al. have studied the anti-inflammatory effect of
subcutaneously delivered dexamethasone for one month in minipigs. However, they delivered
large amounts of dexamethasone (ranging from 3 to 42 mg/implant or 0.05 to 0.7 mg/Kg body
weight). Such large amounts of dexamethasone are not necessary for local prevention of FBR, can
cause systemic effects, and cannot be incorporated around miniaturized implants (for example
biosensors of a few millimeters in length). Accordingly, a method to deliver small amounts (less
than one mg) of dexamethasone effectively to prevent FBR in a large animal model is necessary.
It was previously determined that: a) high dexamethasone loading in PLGA microspheres is
necessary to provide sufficient drug to last for a one-month implantation period in minipigs; and
b) a lag phase in the dexamethasone release profile is detrimental in preventing FBR in minipigs.
Accordingly, in the present work a new PLGA microsphere formulation with high drug loading
efficiency and no lag phase was developed. The new PLGA formulation was prepared via
dexamethasone-PLGA co-precipitation rather than dexamethasone crystal dispersion in the PLGA
matrix and its anti-FBR efficacy was tested in Gottingen minipigs for a one-month implantation
period.
3.2. Materials and Methods
3.2.1. Materials
Dexamethasone was purchased from Cayman Chemical Company (Ann Arbor, MI). Highmolecular weight poly(vinyl alcohol) (HMW-PVA, MW 30–70 kDa), was purchased from
Polysciences, Inc. (Warrington, PA) and low-molecular weight PVA (LMW-PVA, 99 %
hydrolyzed, MW 133 kDa) was purchased from Sigma-Aldrich (St. Louis, MO). PLGA Resomer®
RG503H (inherent viscosity 0.32–0.44 dl/g) was a gift from Boehringer-Ingelheim and PLGA
DLG2A (inherent viscosity 0.15–0.25 dl/g), was a gift from SurModics Pharmaceuticals
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(Birmingham, AL). Methylene chloride and dimethyl sulfoxide (DMSO, ACS grade) were
purchased from Fisher Scientific (Pittsburghm, PA).
3.2.2. Microsphere preparation
50 mg of dexamethasone were dissolved in a small amount of DMSO (0-200 μl). 200 mg
PLGA were dissolved in 0.4 ml of DCM in a 50-ml Teflon vial. The dexamethasone solution was
transferred into the polymer solution and vortexed at 3,000 rpm for 10 s to achieve a homogenous
mixture. 10 or 20 ml of aqueous phase consisting of 1% w/v PVA in water and 0-30% v/v DMSO
were added in the Teflon vial while vortexing at 3,000 rpm. The resulting emulsion was diluted in
380 ml Milli-Q water and was held at ambient temperature and pressure for 3 hours under stirring
at 600 rpm. After 3 hours, stirring continued under vacuum for 30 min to remove any residual
DMSO. The hardened microspheres were collected and any free PVA, DMSO and dexamethasone
was removed via three centrifugation and washing (Milli-Q water) cycles at 3,500 rpm for 2 min
each. The microspheres were subsequently freeze-dried and stored at 4 °C until further use.
3.2.3. Optimization of microsphere preparation method
The above method was optimized for dexamethasone solution volume, DMSO concentration
in the aqueous phase, total volume of aqueous phase and dilution in Milli-Q water. The emulsions
were monitored under a polarized light microscope (PLM) in order to pinpoint the position and
timing of dexamethasone precipitation (inside vs. outside the emulsion droplets). The optimized
formulation (slow homogeneous precipitation of dexamethasone within the emulsion droplets) was
tested for burst release (dexamethasone released after 24 hours incubation at 37 °C, in 10 mM
PBS) and was chosen for the remaining studies. A formulation where dexamethasone was not
dissolved in DMSO but was suspended in the polymer solution was used as a negative control.
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3.2.4. Characterization of PLGA microspheres
Particle size: An Accusizer 780 (Particle Sizing Systems) was used to measure the particle size of
the PLGA microspheres. 3-5 mg of dried microspheres were suspended in 1 ml of 0.1% w/v PVA
solution, bath-sonicated for 10 seconds (to break up any aggregates) and analyzed for volumebased average size.
Dexamethasone loading: 5 mg of dried microspheres or composites were dissolved in 1 ml DMSO
and then diluted 10 times in phosphate buffered saline (PBS) pH 7.4. Dexamethasone
concentration

was

determined

via

RP-HPLC

(PerkinElmer,

Inc.).

Mobile

phase:

acetonitrile/water/phosphoric acid (30/70/0.5%, v/v/v); column: Zorbax® C18 (4.6 mm×15 cm);
detection wavelength: 240 nm; flow rate: 1 ml/min.
3.2.5. Preparation of composite coatings
150 mg PLGA microspheres and 9 mg crystalline dexamethasone were added to 1 ml of PVA
solution in water (5% w/v) and the mixture was bath-sonicated for 10 seconds to achieve a
homogenous suspension. Please note that the coatings were spiked with crystalline dexamethasone
to achieve approximately 100 μg dexamethasone release from each implant within the first 24
hours (due to the low burst release of the microspheres). This amount of burst release is necessary
to prevent the first part of the FBR (acute inflammation) based on our previous studies. Small
silicon chips (5x0.5x0.5 mm, used to mimic small implantable devices) were sandwiched between
a two-piece grooved mold containing the microsphere/PVA suspension. The mold was subjected
to three freeze-thaw cycles (2 h at -20 °C, 1 h at ambient temperature) to physically cross-link the
PVA solution into a hydrogel that encloses the silicon chips. The coated chips were removed from
the mold and cut into 7 mm length pieces, air-dried for 3 hours and stored at 4 °C until further use.
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3.2.6. In vitro release testing of the composite coatings
Composites were placed in 10 ml of 10 mM PBS with 0.1% w/v sodium azide in amber vials.
The vials were placed in a water-bath at 37 °C with stirring (100 rpm). The entire media volume
was replaced periodically to ensure maintenance of sink conditions (total dexamethasone
concentration in the media never exceeded 10% of the equilibrium solubility) and avoid the
complication of dexamethasone degradation. The concentration of dexamethasone in the media
was measured via HPLC as described above.
3.2.7. In vivo study
Six female Gottingen minipigs (4 months old) were used in this study. Three types of
composites were studied: (A) coated chips with no dexamethasone, using blank PLGA
microspheres as a negative control; (B) coated chips with optimized dexamethasone-loaded PLGA
microspheres and crystalline dexamethasone; and (C) composites without silicon chips at the core
with dexamethasone-loaded microspheres and crystalline dexamethasone. Group C was
investigated in case the dexamethasone loaded in group B was insufficient to prevent FBR. Each
minipig received three implants (subcutaneously injected at the back of the animals through a 16
G needle) on days 0, 9, 16, 23 and 27 and the animals were sacrificed on day 30. This resulted in
samples being excised 3, 7, 14, 21 and 30 days after implantation. Excised composites with the
surrounding tissue were fixed in 10% buffered formalin, and thin sections (20 μm) were stained
using Hematoxylin & Eosin staining (H&E). H&E staining was chosen instead of Masson’s
trichrome (which stains collagen fibers blue). Due to the highly collagenous nature of swine
subcutaneous tissue, slides that were stained with Masson’s trichrome did not differentiate
cytoplasm, interstitial fluid, and collagen deposition, since everything was stained blue. All animal
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studies were reviewed and approved by the University of Connecticut’s Institutional Animal Care
and Use Committee.
3.2.8. Statistical analysis
All reported values are average values ± standard deviation based on three repetitions. The
histological data were of a qualitative nature (presence or absence of inflammation) and
representative images are shown.
3.3. Results
3.3.1. Optimization of microsphere preparation method
Rather than the typical method of suspending dexamethasone crystals in a PLGA solution, in
this work the encapsulation of dexamethasone in PLGA microspheres was achieved by coprecipitation of dexamethasone and PLGA. The process was optimized in a pilot study where the
precipitation of dexamethasone was visualized via PLM. Figure 3.1 shows two characteristic
images: a) non-optimized process (no added DMSO in the external water phase which would have
slowed down dexamethasone precipitation) where the dexamethasone crystals are observed
outside the polymer phase (emulsion droplets); and b) optimized process where the dexamethasone
crystals are located inside the polymer phase (emulsion droplets).
The optimized process is as mentioned in the Methods section 2.2, with the following
specifications: 100 μl DMSO used to dissolve 50 mg of dexamethasone; 20 ml total volume of
external aqueous phase; 30% v/v DMSO in the external aqueous phase; and primary emulsion
dilution in 380 ml Milli-Q water. The optimized formulation was compared with the negative
control formulation and representative images are shown in Figure 3.2.
3.3.2. Microsphere characterization
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The optimized PLGA microspheres had a dexamethasone loading of 9 ± 0.13 % w/w, burst
release (within 24 hours at 37 °C in 10 mM PBS pH 7.4) of 1.22 ± 0.17 %, and average size (based
on volume distribution) of 36.36 ± 7.79 μm.
3.3.3. In vitro release
The release profile of dexamethasone from the composite coatings with the optimized PLGA
microsphere formulation is shown in Figure 3.3. During the first 24 hours approximately 40 % of
dexamethasone was released, which is as expected since the crystalline dexamethasone added to
the composites accounted for 40 % of the total dexamethasone. A further 15 % was released during
days 2 and 3. From day 4 onwards, sustained release of dexamethasone was observed, which
exceeded 90 % of the total amount of drug in the composites by day 45. This portion of the release
profile was approximately zero order with R2 = 0.9931.
3.3.4. In vivo evaluation of the anti-FBR properties of the composite coatings
Figure 3.4 shows the progress of the FBR from day 3 to day 30 post-implantation for control
implants (coated with blank composite coating, no dexamethasone). The results are consistent with
what has been reported previously, i.e. inflammatory cell accumulation observed on day 3 and
collagen deposition from day 7. A fibrous capsule can be seen from day 14 onwards.
As shown in Figure 3.5, silicon chips coated with dexamethasone-releasing composites
negated the FBR for the 30-day implantation period. No accumulation of inflammatory cells or
fibrous encapsulation was visible in any of the tissue samples.
The same observation has been made when the composites without silicon chips in their inner
core were tested, as shown in Figure 3.6.
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3.4. Discussion
Similarities between human and swine skin make the Gottingen minipig a good large animal
model to investigate the prevention of FBR to subcutaneous implants26. In the previous chapter, it
has been determined that minipigs require higher levels of dexamethasone released in the local
microenvironment to prevent FBR compared to rats. In addition, the existence of a release lag
phase between days 1 and 10 was detrimental to the anti-FBR effect of the composites in the
minipig model but not in the rat models. In this work, we utilized the knowledge gained from our
previous studies to develop a one-month dexamethasone-releasing composite coating that was
capable of preventing FBR in minipigs.
Previously, dexamethasone has been encapsulated in PLGA microspheres by suspending
micronized dexamethasone crystals in a PLGA solution and further emulsifying the suspension in
an aqueous phase followed by organic solvent extraction and microsphere formation23, 27, 28. This
formulation showed a lag phase in the one-month release profile21, 29, 30. It was hypothesized that
the lag phase was due to poor drug distribution in the microsphere matrix and that improving the
drug distribution would minimize the lag phase.
Instead of suspending dexamethasone crystals in the PLGA solution, a co-solvent system
(DCM/DMSO) to dissolve both dexamethasone and PLGA in the oil phase was used. Further, the
process parameters were adjusted to ensure that dexamethasone precipitates immediately before
PLGA. This facilitated the encapsulation of dexamethasone as small crystals throughout the
polymer matrix. The inclusion of DMSO in the outer water phase (30% v/v) was crucial in
achieving this, as it slowed down the diffusion of DMSO from the oil to the water phase and thus
the precipitation of dexamethasone. Moreover, the ratio of the co-solvents in the inner oil phase
was crucial to achieving timely dexamethasone precipitation and was optimized at 4:1
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DCM:DMSO by volume. Lastly, dilution of the emulsion in a large volume of water ensured that
PLGA precipitated immediately after dexamethasone precipitation. These parameters were
optimized by utilizing PLM to monitor drug precipitation during processing, as shown in Figure
3.1 and Figure 3.2.
The optimized microsphere formulation was incorporated into the PVA hydrogel and was
tested for in vitro release. The composites were spiked with crystalline dexamethasone to
accommodate the lack of dexamethasone release during the first 24 hours. This additional
dexamethasone accounted for 40% of the total drug content of the composites. As expected, the
free dexamethasone was released rapidly from the composites, with 40% release during the first
24 hours. This release is crucial to negating the acute inflammatory phase. A further 15% of
dexamethasone was released during days 2 and 3, which is likely due to release of dexamethasone
encapsulated near the surface of the microspheres or inside smaller microspheres. From day 4 until
day 45, dexamethasone was constantly released at an approximately zero order rate (more than
90% cumulative drug release). The slight deviation from linearity (R2 = 0.9931) during this release
period may be due to the wide size distribution of the microspheres, with the smaller microspheres
contributing more near the beginning of the release and the larger microspheres contributing more
towards the end of the release profile. Another possible reason for this deviation from linearity is
the degradation pattern of PLGA, which undergoes auto-catalyzed degradation through the
generation of hydrogen ions that facilitate hydrolysis.
Composites made with the optimized PLGA formulation were tested in Goettingen minipigs
for their efficacy in preventing the FBR for one month. It was determined that the FBR can be
completely negated by the constant release of dexamethasone throughout the implantation period.
In addition, implants made of composites with no silicon chips in their core (to allow for higher
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dexamethasone loading) were investigated and it was shown that these also prevented FBR. The
need for higher dexamethasone doses in minipigs compared to rats (which were the focus of
previous research) is likely due to the highly collagenous nature of the swine subcutaneous tissue.
This results in more severe and earlier appearance of fibrosis. While the in vivo studies were
conducted for a period of 30 days, the in vitro release studies revealed dexamethasone release for
45 days. Accordingly, these composites may be useful to prevent FBR for more than 30 days,
however, this has not yet been tested in vivo and will be part of future investigations.
3.5. Conclusions
A novel method for the preparation of microspheres containing insoluble drugs was developed
to achieve homogeneous drug distribution, high loading and low burst release. Dexamethasone
microspheres prepared by this method, together with crystalline dexamethasone, were utilized in
microsphere/hydrogel composite coatings to achieve an approximately 40% burst release followed
by a constant drug release pattern with no lag phase. This microsphere/hydrogel composite coating
formulation successfully prevented FBR in a large animal model for a period of one month via
localized release of low doses of dexamethasone (approximately 10 μg per day, which is close to
1000 times below the level that which would result in any systemic effects (0.75 to 9 mg per day).
To the best of the authors’ knowledge, this is the first time that such low doses of dexamethasone,
suitable for miniaturized medical devices such as biosensors, have been used to prevent FBR in a
large animal model.
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Chapter 4
Prevention of the Foreign Body Reaction and Promotion of Angiogenesis around
Subcutaneous Implants
Abstract
Dexamethasone-releasing PLGA poly(lactic-co-glycolic acid) microsphere/PVA (polyvinyl
alcohol) hydrogel composite coatings have been shown to prevent the foreign body reaction (FBR)
to subcutaneous implants in small and large animal models. Such coatings were developed to
extend the lifetime of implantable biosensors. However, long-term exposure of tissue to low levels
of dexamethasone results in a reduction in blood vessel density due to the anti-angiogenic effect
of dexamethasone. This mild effect, while not threatening to the subject’s health, may interfere
with analyte detection and sensor response time over the long-term. VEGF has been previously
incorporated into these coatings and the anti-angiogenic effect of dexamethasone was reduced.
The present work focused on administration of combinations of three tissue response modifiers
(TRMs), dexamethasone, VEGF and PDGF (platelet derived growth factor) which prevent the
FBR, increase angiogenesis and promote blood vessel maturation (which increases blood flow),
respectively. To minimize any potential interference among the three TRMs (for example, PDGF
increases fibrosis), the relative doses of dexamethasone, VEGF and PDGF were adjusted. It was
determined that: a) all three TRMs are required for maximum promotion of angiogenesis, blood
vessel maturation and prevention of the FBR; b) VEGF has to be administered at higher doses than
PDGF; c) an increase in dexamethasone dosing must be accompanied by a proportional increase
in growth factor dosing; and d) modification of the TRM ratio can achieve a constant capillary
density throughout the implantation period which is important for applications such as biosensors
to maintain sensitivity and a stable sensor baseline.
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4.1. Introduction
Biosensors, defined as analytical devices that detect biological analytes, have progressed in
their development and miniaturization such that fully-implantable sensors (usually in the
subcutaneous tissue) will become a reality in the near future1-12. These sensors will provide realtime, continuous monitoring of analytes, such as glucose, which are currently being monitored
intermittently. Diabetic patients are a major group that will benefit from the realization of
implantable biosensors, since tight blood glucose control is paramount to diabetic health.
Once implanted, biosensors are attacked by the body’s defense mechanism, a cascade of events
collectively known as the foreign body reaction (FBR) which results in the encapsulation of
biosensors in a fibrous membrane that isolates them from the surrounding tissue and thus renders
them ineffective13, 14. The FBR and its prevention have been a research focus during the past
decades; the most common method to prevent the FBR is by the continuous administration of an
anti-inflammatory agent, most commonly dexamethasone6, 13-16. Dexamethasone is popular due to
its high efficacy and potency which result in only small amounts of the drug being required for
long-term action. However, long-term exposure of a tissue to low levels of dexamethasone results
in reduction in blood vessel density in the local area due to dexamethasone’s anti-angiogenic
effect17-19. This mild effect, while not detrimental to the subject’s health, may interfere with analyte
detection and sensor the response time.
Glucose diffuses passively from the blood to the subcutaneous tissue where it can be detected
by an implanted biosensor. The time it takes for glucose to travel from the capillary wall to the
sensor surface is dependent on the distance it has to cover, and typically ranges from 6 to 15
minutes20. Long-term exposure of dexamethasone decreases the number of capillaries available
for glucose diffusion to the sensor, as well as increases the average distance between the capillaries
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and the sensor surface. Both effects may significantly increase sensor response lag time as well as
sensitivity. Accordingly, growth factors that promote angiogenesis can be administered alongside
dexamethasone in order to prevent dexamethasone-induced ischemia and reduce glucose sensor
lag times. VEGF (vascular endothelial growth factor) has successfully been administered with
dexamethasone through poly(lactic-co-glycolic acid) (PLGA) microspheres embedded in a
polyvinyl alcohol (PVA) hydrogel over a one-month period and an increase in capillary density
was observed21. To further increase the capillary density around the implants, the current work
focuses on administration of dexamethasone, VEGF and PDGF (platelet derived growth factor).
VEGF promotes the migration of endothelial cells to the site, which form new branches on existing
blood vessels22-25. PDGF promotes the maturation of the new branches by attracting pericytes that
form an outer cellular layer on the new branches and connect venous and arterial blood flow26-29.
It is known that angiogenesis and the FBR have some mechanistic overlap; cytokines that
promote branching of existing blood vessels and recruitment of endothelial cells (primarily VEGF)
exacerbate acute inflammation and inhibit chronic inflammation (which starts with the activation
of fibroblasts)30-32. On the other hand, cytokines that promote the maturation of new blood vessel
branches (primarily PDGF), via the recruitment of pericytes, promote chronic inflammation33-36.
In addition, dexamethasone is well known to inhibit angiogenesis. It is therefore evident that the
simultaneous release of these three molecules in a tissue will result in significant interference in
their respective roles. In the current work, composite implants containing combinations of
dexamethasone, VEGF and PDGF were investigated in the subcutaneous tissue using a rat model.
The tissue surrounding the implants was examined via histological evaluation for prevention of
the FBR and concurrent promotion of angiogenesis. Adjustment of the relative ratios of the three
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TRMs eliminated interference among the TRMs that was observed for some of the composite
combinations.
4.2. Materials and Methods
4.2.1. Materials
Dexamethasone was purchased from Cayman Chemical Company (Ann Arbor, MI). VEGF,
PDGF and their respective ELISA quantification kits were purchased from Peprotech (Rocky Hill,
NJ). High-molecular weight polyvinyl alcohol (HMW-PVA, MW 133 kDa), was purchased from
Polysciences, Inc. (Warrington, PA). Low-molecular weight PVA (LMW-PVA, 99% hydrolyzed,
MW 30-700 kDa), bovine serum albumin (BSA), and BSA-FITC were purchased from SigmaAldrich (St. Louis, MO). PLGA Resomer® RG503H (inherent viscosity 0.32–0.44 dl/g) was a gift
from Boehringer-Ingelheim. Methylene chloride was purchased from Fisher Scientific
(Pittsburghm, PA). Sprague Dawley rats were purchased from Charles River Laboratories
(Willimantic, CT).
4.2.2. Formulation of protein microspheres
In a 50-ml Teflon vial, 500 mg of PLGA were added with 2 ml methylene chloride (DCM).
After the polymer was dissolved, 200 μl of the protein phase (100 mg/ml BSA with either 5 μg
VEGF (V_MS), 5 μg PDGF (P_MS) or 5 μg VEGF and 2.5 μg PDGF (VP_MS)) were added to
the polymer solution. The vial was vortexed at 3,000 rpm for 10 seconds and homogenized at
10,000 rpm for 30 seconds to achieve a water-in-oil primary emulsion. A secondary water-in-oilin-water emulsion was made by adding 10 ml water phase (1% w/v of LMW-PVA, with or without
2% w/v NaCl) and vortexing at 3,000 rpm for 10 seconds. The secondary emulsion was diluted
with 10 ml of Milli-Q water to speed up polymer precipitation and microsphere formation. The
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diluted emulsion was kept under vacuum on a horizontal shaker at 300 rpm for 3 hours. The
hardened microspheres were purified to remove LMW-PVA and non-encapsulated drug via three
centrifugation cycles (2 min, 3,500 rpm), freeze dried overnight and stored at -20°C until further
use. Formulations containing 2% w/w FITC-BSA (of the total BSA amount) were prepared to
visualize the protein distribution inside the microspheres. All microsphere preparation steps took
place in a single vial (from polymer dissolution in the organic solvent to microsphere storage), as
demonstrated in Figure 4.1.
4.2.3. Formulation of dexamethasone microspheres
Dexamethasone-containing microspheres were prepared as above with the 200 μl protein
solution replaced by 100 mg of crystalline dexamethasone. A homogenous drug suspension in the
polymer solution was achieved following 2.5 min of homogenization at 10,000 rpm.
4.2.4. Microsphere characterization
Drug loading (dexamethasone): 5 mg of dried microspheres were dissolved in 1 ml DMSO
and then diluted 10 times in phosphate buffered saline (PBS) pH 7.4. Dexamethasone
concentration was determined via RP-HPLC (PerkinElmer, Inc.). Mobile phase 35% acetonitrile
in water, 0.1% phosphoric acid; column C18 500x03 mm; and detection wavelength 240 nm.
Drug loading (growth factors): 2 mg of dried microspheres were dissolved in 1 ml acetone,
and the undissolved pellets were washed and collected via three centrifugation cycles (12,000 rpm,
5 min) and dried under vacuum for 30 min to remove acetone. The pellets, which contained the
proteins, were reconstituted in 1 ml of PBS containing 0.1% Tween 20. VEGF and PDGF ELISA
kits were used to quantify the growth factor concentration in the reconstituted solutions, as per the
manufacturer’s instructions.

41

Particle size: An Accusizer 780 (Particle Sizing Systems) was used to measure the particle
size of the PLGA microspheres. 3-5 mg of dried microspheres were suspended in 1 ml of 0.1%
w/v LMW PVA solution, bath-sonicated for 10 seconds to break any aggregates and analyzed for
volume-based average size.
Confocal microscopy: A Nikon A1R Spectral confocal microscope was used to visualize
protein distribution inside the microspheres. Microspheres were suspended in distilled water prior
to imaging, and FITC-BSA was detected at excitation and emission wavelengths of 494 and 518
nm, respectively.
4.2.5. Fabrication of composites
A predetermined amount of PLGA microspheres were added to 1 ml of HMW-PVA solution
in water (5% w/v) and the mixture was bath-sonicated for 10 seconds to achieve a homogenous
suspension. The suspension was fed into stainless steel tubes with inner diameter 1.5 mm and
subjected to three freeze-thaw cycles (2 h at -20°C, 1 h at ambient temperature) to physically crosslink the HMW-PVA solution to form a hydrogel. The gels were removed from the tubes and cut
at 5 mm length pieces, air-dried for 3 hours and stored at -20°C until further use. The different
groups of composites prepared and their compositions are shown in Table 4.1.
4.2.6. Investigation of VEGF-to-PDGF ratio
Spraque Dawley rats (male, 150-200 g) were used as a small animal model (6 per group). Each
rat was implanted with composites C, D, DV, DVP, and D2VPa (as defined in Table 4.1 above)
on the dorsal area. Each member of a group of rats was implanted with four composites of the
same type. Implants were spaced at least 2 cm apart to ensure no interference. Rats were euthanized
30 days after implantation. After euthanasia, the composites with surrounding subcutaneous tissue
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and skin were removed and fixed in 10% buffered formalin solution for 24 hours. They were then
processed at UConn’s pathobiology services, embedded in paraffin blocks and cut into 20 μmthick sections. The samples were immune-stained against smooth muscle actin (sma), which stains
mature blood vessels.
4.2.7. Investigation of dexamethasone-to-growth factor ratio
Based on the outcome of the growth factor ratio study, this investigation included composites
D, DV, D2VPb as well as one with a higher dexamethasone dose (2D2VP). The study design was
as described above with the following differences: Rats were euthanized on different days in
groups of 6 (day 3, 7, 14, 21, and 30 following implantation). In addition to immune-staining
against sma, the samples from the final study were also stained using a standard H&E protocol to
monitor the anti-FBR effect of the composites. Anti-sma-stained tissue slides were examined via
light microscopy, and the total number of capillaries within a distance of 200 μm around the
implants were blind-counted, and the average values and standard deviations were calculated from
three samples.
All animal studies were reviewed and approved by the University of Connecticut’s Institutional
Animal Care and Use Committee.
4.3. Results
4.3.1. Microsphere preparation and characterization
Protein distribution inside the PLGA microspheres was optimized in a pilot study (using only
BSA as model protein). 2% w/v of NaCl was added to the outer water phase to induce removal of
the inner water phase through osmosis while leaving the protein molecules inside the polymer
matrix. The microspheres were characterized for protein distribution, drug loading and burst
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release. It was determined that by incorporation of NaCl in the outer water phase, protein
distribution in the microsphere matrix improved significantly and the burst release was reduced,
as shown in Figure 4.2.
Dexamethasone- and growth factor-loaded PLGA microspheres were prepared with the
optimized method described above, and were characterized for drug loading and particle size as
shown in Table 4.2.
4.3.2. VEGF-to-PDGF ratio
The relative amounts of VEGF and PDGF were changed while dexamethasone dosing was
kept constant. Figure 4.3 shows tissue samples around composites C, D, DV, DVP, D2VPa, as
well as normal tissue (N) away from implantation sites at 30 days following implantation. Mature
blood vessel walls stained red. As expected, control implants (C) with no dexamethasone, VEGF
or PDGF, showed fibrosis (blue band around the implant). Implants D, which were loaded with
dexamethasone but no growth factors, showed no fibrosis, and the blood vessel density around
these implants was significantly lower than that of normal tissue. Implants DVP, which were
loaded with equal amounts of VEGF and PDGF showed fibrosis and low blood vessel density near
the surface of the implants. Implants D2VPa with a VEGF and PDGF ratio of 2:1 showed
angiogenesis, with capillaries oriented around the implant.
4.3.3. Adjustment of dexamethasone dose
Based on the results of the previous study, implants D, DV, D2VPb and 2D2VP were used to
investigate their anti-FBR effect throughout a one-month period. Figure 4.4 shows representative
tissue sections from day 3 to day 30 following implantation for the different composites. No
inflammation (infiltration of inflammatory cells present on day 3 and fibrotic band present from
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day 14 onwards) was observed in any of the composites. This was expected for composites D
which have previously been studied for their anti-FBR effect and were used as a control here.
Composites that contained VEGF or combinations of VEGF and PDGF in addition to
dexamethasone also showed no inflammation. In the combination composites (D2VPb and
2D2VP), dexamethasone was loaded at two doses to confirm that the minimum effective dose
previously determined for composites with only dexamethasone and VEGF is effective in the
combination coatings.
Figure 4.5 shows the angiogenic effect of the composites 7, 14, 21 and 30 days following
implantation at a low magnification (10x). Higher-magnification (40x) images are shown in Figure
4.6 and the capillary density around the implants was quantified as reported in Figure 4.7. The
highest angiogenesis throughout the implantation period was achieved with composites D2VPb
(P<0.001 compared to the control group), and the capillaries were oriented around the implant.
Composites D2VPb were the only composites with capillaries around their entire perimeter, as
shown in Figure 4.5.
4.4. Discussion
Accurate quantification of angiogenesis in the subcutaneous tissue is challenging, and different
approaches have been applied by research groups depending on each application37-41. For example,
in studies where ischemia was investigated in large parts of a tissue, the perfusion of the tissue
(blood volume reaching a specific area) was measured via imaging techniques such as ultrasound42, 43. For applications that investigated small tissue areas, such as in the studies reported
here, histological evaluation is the most common method of assessment of angiogenesis. In the
current studies, angiogenesis was monitored via immune-staining against sma, which is present on
the surface of mature blood vessels (vessels with connected venous and arterial branches)44-46.
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Since the delivery system presented here was developed for implantable biosensors, the area
nearest to the implant (200 μm from the implant surface) was utilized in counting blood capillaries.
This quantification approach revealed significant increase in capillary density in the immediate
vicinity of the implant for composites with the three-TRM combinations. In addition, it is
important to consider the capillary size and distribution around the implants since these factors
will affect the total amount of glucose reaching the implant surface and the spatial distribution of
glucose in the tissue, respectively. Accordingly, low- and high-magnification images of the tissue
surrounding the implant were analyzed.
Biosensors rely on analytes (e.g. glucose) to diffuse from the blood to the subcutaneous tissue
and reach the sensor surface for their functionality. It has been reported previously that concurrent
release of dexamethasone and VEGF can prevent the FBR and promote angiogenesis over the
long-term in rats21. In this work, dexamethasone, VEGF and PDGF were delivered simultaneously
and their relative doses were adjusted to achieve the highest capillary density at minimal distance
from the implant surface while eliminating interference between the angiogenic and antiinflammatory effects of these three TRMs.
Initially, the dexamethasone dose was kept constant (at the dose previously optimized to
prevent FBR for implants coated with composites containing only dexamethasone) and the relative
VEGF and PDGF amounts were varied. It was determined that delivering equal amounts of VEGF
and PDGF alongside dexamethasone interfered with the anti-FBR effect of the latter, and a fibrotic
band was observed around the implant (DVP). In addition, no new capillaries developed close to
the implant; this is probably due to the presence of the fibrotic band obstructing subsequent VEGF
and PDGF release to the local tissue. It was determined that reducing the amount of PDGF loaded
in the implants by half (D2VPa) eliminated interference with the anti-FBR effect of
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dexamethasone, and significant increase in blood vessel density was observed compared to the
control group (D).
Based on these results, the VEGF-to-PDGF ratio was kept constant at 2:1, and both growth
factors were loaded in a single population of microspheres in this ratio (VP_MS). To study the
extent of the interference between the three TRMs, a higher dexamethasone dose was investigated.
It was determined that the anti-FBR effect of the implants remained intact, while the capillary
density was reduced and the average capillary-to-implant distance was increased. This indicates
that in order to preserve the angiogenic effect of such composites at higher dexamethasone doses,
the growth factor dose needs to be increased proportionally.
In the interest of improving biosensor functionality (lag time and sensitivity), it is important to
note that the formulation that showed maximum angiogenic effect (D2VPb) also had a higher
capillary density at day 30 compared to the other time points. This variation may potentially affect
biosensor functionality in terms of stable baseline readings. However, this variation in capillary
density with time did not occur in formulation 2D2VP (which had a higher dexamethasone dose).
4.5. Conclusions
In this work, combinations of dexamethasone, VEGF and PDGF were delivered for the first
time to prevent FBR and promote angiogenesis. Visual examination of histological images at low
and high magnifications combined with capillary density measurements around the implants was
necessary for data interpretation. It was determined that: i) prevention of FBR along with
maximum angiogenesis around the implants requires all three TRMs in specific relative amounts;
ii) VEGF has to be administered at higher doses than PDGF; iii) an increase in dexamethasone
dosing reduces the angiogenic effect of the composites and must be accompanied by a proportional

47

increase in growth factor dosing; and iv) capillary density throughout the implantation period is a
potential factor that may affect biosensor lag time and sensitivity.
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Chapter 5
Continuous Metabolic Monitoring Based on Multi-Analyte Biomarkers to Predict
Exhaustion
Abstract
This work introduces the concept of multi-analyte biomarkers for continuous metabolic
monitoring. The importance of using more than one marker lies in the ability to obtain a holistic
understanding of the metabolism. This is showcased for the detection and prediction of exhaustion
during intense physical exercise. The findings presented here indicate that when glucose and
lactate changes over time are combined into multi-analyte biomarkers, their monitoring trends are
more sensitive in the subcutaneous tissue, an implantation-friendly peripheral tissue, compared to
the blood. This unexpected observation was confirmed in normal as well as type 1 diabetic rats.
This study was designed to be of direct value to continuous monitoring biosensor research, where
single analytes are typically monitored. These findings can be implemented in new multi-analyte
continuous monitoring technologies for more accurate insulin dosing, as well as for exhaustion
prediction studies based on objective data rather than the subject’s perception.
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5.1. Introduction
Metabolic monitoring is the periodic recording of metabolic markers that give information on
specific metabolic pathways. Diabetes mellitus, obesity and intense physical activity are a few
examples where close metabolic monitoring is necessary1-3. This is routinely done in a noncontinuous manner, where the individual records their blood glucose, body weight, blood pressure,
etc. over various periods of time. Technological advances on wearable and/or implantable devices
have initiated the transition to real-time, continuous monitoring4-8. However, monitoring devices
have several shortcomings: they trigger the foreign body reaction which results in loss of
functionality within a few days, they cannot be implanted directly in the bloodstream, and they
typically record only single analytes. The foreign body reaction to implantable medical devices
has been shown to be prevented by incorporating drug-eluting biocompatible coatings8-10. When a
device that is implanted in a peripheral tissue such as subcutaneous tissue is used to monitor analyte
changes in the blood, loss of sensitivity and lag times are observed11. This is due to the fact that
analytes have to diffuse from the bloodstream to the interstitial fluid before being detected.
Exhaustion, also known as fatigue, is the inability of muscle to continue an ongoing physical
activity12. The perception of exhaustion is highly subjective, and consequently the assessment of
a subject’s endurance is currently based on semi-empirical observations that link the fitness and
current state (e.g. heart rate) of each subject with pre-recorded performance levels13,14. However,
exhaustion has been linked to several metabolic pathways and therefore a close examination of the
metabolic processes involved in physical activity could facilitate a more accurate prediction of
exhaustion. Depletion of fuel stored in the muscle (i.e. creatine and glycogen, that are readily
accessible as an energy source), as well as accumulation of metabolic byproducts (e.g. chloride
and potassium ions and lactic acid) are considered the causes of exhaustion15,16. These metabolic
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events take place in the exercising muscle, a body compartment that is not available for real-time,
continuous monitoring via implantable devices mainly due to the trauma associated with
intramuscular implantations.
In this work, exhaustion detection in the subcutaneous tissue using multiple analytes combined
into multi-analyte biomarkers was investigated. Single-analyte monitoring, such as glucose
monitoring, creates blind spots in the recorded metabolic state since a single analyte cannot
account for all pathways involved in a given metabolic event. It is hypothesized that monitoring
of two analytes (glucose and lactate) will offer a more complete view into metabolic changes
during exercise that lead up to exhaustion. In the context of exhaustion prediction, glucose and
lactate are suitable candidates for multi-analyte monitoring: glucose is the primary energy source
of muscle cells, and lactate is the main by-product of anaerobic metabolism during intense activity.
To test the above hypothesis, exercise experiments were conducted in normal as well as type
1 diabetic rats. Diabetic rats were included in the study design since one application of this work
will be to improve the health of diabetic athletes. External observations (commencement of
exercise, running speed, and onset of exhaustion) were correlated with internal shifts in
metabolism (glucose and lactate as single readings or combined into multi-analyte biomarkers)
recorded in the subcutaneous tissue and the blood. Microdialysis was used to monitor glucose and
lactate in the subcutaneous tissue and the blood. Microdialysis is a reliable technique that has been
used extensively in laboratory settings to monitor analyte changes in various tissues.
5.2. Materials and Methods
5.2.1. Animal models
Male Sprague Dawley rats (6 weeks old, 150-170 g) were used as the normal animal model
(n=6). One group of rats was injected with streptozotocin (60 mg/kg body weight, IP) to induce
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type 1 diabetes (n=3). Additionally, Zucker Diabetic Fatty (ZDF) rats, an obesity animal model,
were used in the preliminary studies (n=3). However, data from ZDF rats were not included in this
manuscript since these animals could not perform intense exercise due to their physical condition.
All animal studies were done in accordance with the approved guidelines. All studies were
reviewed and approved by the University of Connecticut’s Institutional Animal Care and Use
Committee (IACUC) prior to the beginning of the experiments.
5.2.2. Microdialysis
Microdialysis was used to monitor analytes in the blood and subcutaneous tissue. Each rat was
implanted with one microdialysis catheter (20 kDa molecular weight cut-off, CMA Microdialysis
AB) in the subcutaneous tissue and one in the jugular vein. Catheterization took place with the aid
of a guiding needle as per the manufacturer’s instructions.
5.2.3. Exercise experiments
Rats implanted with two microdialysis catheters were placed in a forced exercise treadmill
(IITC, Inc.). An isotonic liquid (Ringer’s solution) was pumped through the microdialysis catheters
at 5 μl/min speed rate (syringe pump, Harvard Apparatus) and samples were collected every 10
minutes (preliminary studies) and every 6 minutes for the all other studies. After an initial resting
period to collect baseline data, exercise commenced at maximum running speed. The maximum
speed varied with each rat and was in the range of 15-17 meters per minute. The onset of
exhaustion was noted when the rats could not keep up at the maximum pace, and the exercise
ended when the rats failed to run at all. A recovery period was allowed after the exercise.
5.2.4. Analyte quantification
YSI 2300 STAT Plus™ (YSI Life Sciences, Inc.) was used to quantify glucose and lactate
molar concentrations in the microdialysis samples. Oxygen and carbon dioxide microelectrodes
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(Microelectrodes, Inc.) were used to determine analyte trends in the microdialysis samples. Since
oxygen and carbon dioxide monitoring was found unsuitable for this application, only the electrode
output is reported to obtain the analyte trend.
5.2.5. Data analysis
Analyte concentrations were plotted against time as shown in the main text of the manuscript.
With the exception of the exhaustion prediction times (which are reported as average values ±
standard deviation), animal data could not be aggregated for statistical analysis due to variability
on the fitness and endurance level of each rat. Representative plots of analyte trends are shown to
showcase the feasibility of multi-analyte biomarkers for exhaustion prediction.
5.3. Results
5.3.1. Choice of analytes to be monitored
Glucose and lactate were chosen as markers based on preliminary studies where blood and
subcutaneous glucose, lactate, oxygen and carbon dioxide were monitored in healthy and obese
animals during light exercise. The results indicated that oxygen and carbon dioxide are not suitable
analytes for predicting exhaustion. As shown in Figure 5.1, oxygen trends did not respond to light
exercise while carbon dioxide values were highly unstable.
5.3.2. Glucose and lactate changes during intense exercise
Figure 5.2a depicts a representative metabolic profile for a healthy rat. Glucose and lactate
changes in the blood and subcutaneous tissue are shown in four zones. A: prior to exercise (baseline
measurements); B: during intense exercise; C: during light exercise (post-exhaustion); and D:
recovery. Since glucose and lactate have to diffuse from the blood to the subcutaneous tissue to be
taken up by the microdialysis catheter, the small differences in blood and subcutaneous values
were expected. A spike in both glucose and lactate levels in the blood as well as the subcutaneous
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tissue are observed upon commencement of exercise, a typical observation when transitioning
from rest to activity. Exhaustion was first observed 57 minutes into the exercise, when the animal
could not keep up and the treadmill speed had to be adjusted. Full exhaustion was observed 30
minutes later, when the animal was unable to continue the exercise. Interestingly, glucose and
lactate showed a trend change around 45 minutes into the exercise, 12 minutes before the first
physical evidence of exhaustion and 42 minutes before full exhaustion (indicated by red ovals).
The exhaustion-prediction window varied from 12 to 20 minutes among the rats, due to varied
endurance levels. The average exhaustion prediction time was 16.17 ± 4.16 min.
Similar observations of exhaustion prediction were made in untreated, type 1 diabetic rats
(Figure 5.2b) with an average exhaustion prediction time of 8.60 ± 3.08 min. However, diabetic
rats did not show a gradual manifestation of exhaustion, but reached full exhaustion immediately.
As shown in Figure 5.2b, glucose as well as lactate build-up was observed. The type 1 diabetic
rats were untreated (they did not receive insulin injections). As a result, glucose released from the
liver as an energy source could not be internalized by muscle cells which failed to perform the
exercise shortly after glucose and lactate build-up stopped. It should be noted that the data from
diabetic rats exhibited one anomaly: the glucose values obtained from the microdialysis samples
were consistently lower than the values obtained from normal rats. This conflicted with glucose
values obtained via tail vein pricking to confirm the diabetic state (>350 mg/dL). However, the
interpretation of the data shown here relies on the trend rather than the absolute values of glucose
and lactate, and this anomaly did not interfere with data interpretation.
The findings described above confirmed our hypothesis that detectable metabolic changes
precede physical manifestations of exhaustion. Accordingly, these changes may be used as a
predictive tool for exercise endurance and exhaustion.
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5.3.3. Multi-analyte biomarker identification
The observations described above are based on blood levels of glucose and lactate (monitored
independently) as these changes were not as evident in the subcutaneous tissue. This poses a
potential problem in translating these findings into subcutaneously-implantable monitoring
platforms. It was hypothesized that by combining glucose and lactate readings into multi-analyte
biomarkers it may be possible to increase the monitoring resolution in the subcutaneous tissue
since glucose and lactate account for aerobic and anaerobic metabolism, respectively. Glucose
(GLU) and lactate (LAC) combinations were investigated. Since one glucose molecule yields two
lactate molecules, the lactate concentration was used directly or multiplied by two to account for
this. The efficacy of the biomarkers to increase the monitoring resolution in the subcutaneous
tissue was tested by measuring the absolute slope changes during two metabolic events: rest-toactivity transition (first peak in Figures 5.2a and 5.2b) and pre-exhaustion trend changes (second
peak in Figures 5.2a and 5.2b). It was determined that combinations of biomarkers were several
times more sensitive to metabolic changes in the subcutaneous tissue compared to the blood as
shown in Figure 3a for normal rats and Figure 3b for diabetic rats. Single analyte changes relative
to the baseline measurements (%CLU and %LAC) also showed higher sensitivity in the
subcutaneous tissue than the blood. The utilization of percent changes of single analytes is not
feasible for continuous monitoring systems as stable baseline measurements are not usually
available outside controlled laboratory environments. This is especially relevant for individuals
undergoing fitness level changes (due to training or disease management) whose metabolic
baseline is continuously shifting, as well as subjects with no control over their activity levels such
as deployed military personnel.
5.3.4. Multi-analyte biomarkers for prediction of exhaustion
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Based on the results shown in Figures 5.3a and 5.3b, 2LAC/GLU was plotted vs. time for
normal and diabetic rats (Figure 5.4a). As shown in this figure, 2LAC/GLU can be used to predict
exhaustion with more accuracy in the subcutaneous tissue than the blood. 3D surface plots of
glucose, lactate, and time were constructed (Figure 5.4b). These plots incorporate all possible
combinations of glucose and lactate and when implemented into standardized exercise routines1727

can provide feedback on the fitness and endurance of the subject. As shown in Figure 5.4b, the

exhaustion-predictive metabolic changes described above in response to exercise are more
profound in areas where glucose and lactate are combined compared to the peripheral regions of
the graph where glucose and lactate are plotted separately.
Discussion
This work explored the potential of the subcutaneous tissue, a device implantation-friendly
space, to be used in continuous metabolic monitoring for exhaustion prediction. The ultimate goal
is to utilize the proof-of-concept presented here to develop exhaustion-predicting algorithms that
rely on holistic metabolic shifts instead of single markers such as heart rate or lactate. An array of
biomarkers that can be used in such algorithms was successfully identified, and furthermore the
concept of constructing 3D biomarker plots was presented.
Continuous monitoring of more than one analyte can reveal the interdependence of different
metabolic pathways and the metabolic flexibility of the individual (the ability to switch from
aerobic to anaerobic utilization of energy and vice versa). Our findings revealed that multi-analyte
biomarkers based on glucose and lactate are far more responsive in the subcutaneous tissue (an
implantation-friendly compartment) than in the blood. This is a significant breakthrough for
subcutaneously-implanted monitoring devices since until now their inability to detect analytes
directly in the blood was considered a handicap.
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The size and shape of the semi-implantable microdialysis probe makes it a good model for
implantable biosensors. In the future, when implantable multi-sensors become available, the
concept of continuous multi-analyte monitoring for exhaustion prediction presented here will be
applied to individualized algorithms paired with such devices. The applications of this concept are
many. Long-term changes in multi-analyte biomarker interdependence are expected to reveal
progress in the training of athletes, management of diabetic patients, development of pre-diabetes
in obese subjects, etc. Here it was shown that multi-analyte biomarkers can be used to predict
exhaustion, which is crucial for diabetic athletes, deployed military personnel, and other high-risk
individuals involved in intense physical activity.
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Chapter 6
Conclusions and Future Studies
6.1. Summary and conclusions
There are currently a number of semi-implantable biosensors on the market that monitor
glucose continuously; these devices, however, lose functionality after 6-10 days due to the tissue
reaction to the implanted (needle-like) portion of the device. As a result, to this day, continuous
glucose monitoring has not been implemented into routine diabetes management. Consequently,
there is a great need for a biosensor that i) functions for prolonged periods of time and ii) has
minimal interference with the daily life of diabetic patients to enable patient compliance. Such a
biosensor will revolutionize diabetes management with additional applicability in the fields of
exercise metabolism as well as remote health monitoring in the military.
To achieve long-term sensor functionality in vivo, modification of the tissue reaction to
implanted biosensors is necessary. A significant amount of research has led to the realization of
biosensor coatings that prevent the FBR and prolong sensor lifetime in vivo. These coatings had
previously been tested in small animal models (normal and diabetic rats). Accordingly, the main
scope of this work was to transfer the technology from small to large animals, expand the coating
functionality to promote angiogenesis alongside prevention of FBR, and explore applications of
sensors in exercise physiology.
Key differences in the FBR to subcutaneous implants between a small (rat) and large (minipig)
animal model were identified for the first time. The onset and severity of fibrosis was determined
to be a significant difference, with minipigs demonstrating earlier onset and more severe chronic
inflammation compared to rats. It was determined that dexamethasone release from the implant
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coatings must be tailored to the species-specific stages of the FBR. In order to counter the more
severe chronic inflammation observed in minipigs compared to rats, dexamethasone release must
be continuous, with no lag phase. The effective dexamethasone dosing regime was 100 μg during
the first day and 10 μg/day thereafter; this regime is applicable to implants of similar size (7 x 0.15
mm) and can be extrapolated to longer implantation periods in minipigs. These findings can
facilitate the dose calculations in the first-in-human studies as porcine skin is the optimal animal
model for dermal formulations.
The species differences that were identified in the first part of this work were utilized to
develop a novel method for the preparation of microspheres containing insoluble drugs with
homogeneous drug distribution, high loading and low burst release. Dexamethasone microspheres
prepared by this method, together with crystalline dexamethasone, were incorporated in
microsphere/hydrogel composite coatings to achieve an approximately 40% burst release followed
by a constant drug release pattern with no lag phase. This microsphere/hydrogel composite coating
formulation successfully prevented FBR in a large animal model for a period of one month via
localized release of low doses of dexamethasone (approximately 10 μg per day, which is close to
1000 times below the level that would result in any systemic effects (0.75 to 9 mg per day). This
is the first time that such low doses of dexamethasone, suitable for miniaturized medical devices
such as biosensors, have been used to prevent FBR in a large animal model.
In order to expand the effects of the composite coatings, combinations of dexamethasone,
VEGF and PDGF were delivered for the first time to prevent FBR and promote angiogenesis in a
rat model. Visual examination of histological images at low and high magnifications combined
with capillary density measurements around the implants was necessary for data interpretation. It
was determined that: i) prevention of FBR along with maximum angiogenesis around the implants
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requires all three TRMs in specific relative amounts; ii) VEGF has to be administered at higher
doses than PDGF; iii) an increase in dexamethasone dosing reduces the angiogenic effect of the
composites and must be accompanied by a proportional increase in growth factor dosing; and iv)
capillary density throughout the implantation period is a potential factor that may affect biosensor
lag time and sensitivity.
Lastly, this work explored the potential of the subcutaneous tissue, a device implantationfriendly space, to be used in continuous metabolic monitoring for exhaustion prediction. The
ultimate goal is to utilize the proof-of-concept presented here to develop exhaustion-predicting
algorithms that rely on holistic metabolic shifts instead of single markers such as heart rate or
lactate. An array of biomarkers that will be used in such algorithms was successfully identified,
and furthermore the concept of constructing 3D biomarker plots was presented. It was determined
that physical exhaustion is preceded by metabolic changes that can be picked up via continuous
monitoring of glucose and lactate in the subcutaneous tissue, indicating that prediction of
exhaustion with an approximately 14-minute window is possible. This will be of paramount
importance for deployed soldiers, diabetic athletes and other high-risk individuals involved in
intense physical activity.
The significant and novel contributions resulting from this work include: i) identification of
key species differences between the FBR in small and large animals; ii) development of a novel
dexamethasone-loaded microsphere fabrication method to accommodate the identified species
differences; iii) prevention of the FBR in a large animal model using small amounts of antiinflammatory drug release; iv) development of a innovative, single-vessel protein microsphere
preparation method with enhanced efficiency, product recovery, and sterility; v) application of
osmosis to encapsulate proteins in polymer microspheres; vi) delivery of dexamethasone, VEGF,
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and PDGF to prevent FBR while promoting angiogenesis in a rat model; vii) adjustment of the
three TRM dose ratios to eliminate interference in their respective actions; ix) application of
continuous, multi-analyte monitoring to predict exhaustion in normal and diabetic rats; and x)
introduction of multi-analyte biomarkers for metabolic monitoring in the subcutaneous tissue with
higher sensitivity than the blood.
The above contributions will advance the field of metabolic monitoring via implantable
biosensors by transferring the technology in large animals for pre-clinical testing, expanding the
sensor lifetime to three months with the use of angiogenic growth factors, and identifying
important biomarkers that can be incorporated in metabolic monitoring algorithms.
6.2. Future studies
The novel microsphere fabrication methods developed here (dexamethasone-loaded and
protein-loaded presented in Chapters 3 and 4, respectively) have been successfully tested in vivo.
Different drugs (small and large molecules) can be encapsulated with these methods to expand the
potential applications of these microspheres. For example, the osmosis-driven microsphere
preparation method can be modified to include both small and large molecules, whereas the drugpolymer co-precipitation method can be further investigated for longer drug release periods.
So far, the electrochemical elements of the sensors were optimized based on testing in small
animals. The biosensor coatings developed and used here to prevent FBR in large animals can be
used in large animal sensor testing. Such testing is necessary in order to transition to the first-inhuman studies of coated implantable biosensors.
It was demonstrated here that adjustment of dexamethasone, VEGF, and PDGF dose ratios
eliminate their interference for one month implantation periods. This effect may be studied for
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longer periods, such as three and six months. It is expected that the ratio that works for one month
will be effective for longer periods as well, however, this needs to be confirmed via careful
examination of longer-releasing formulations. In addition, composites that release dexamethasone,
VEGF, and PDGF have not been used in sensor testing studies. The effect of the capillary density
as well as the capillary distance from the sensor surface has to be studied against sensor
functionality in the long-term.
The importance of multi-analyte monitoring for exhaustion prediction has been demonstrated
here. The next step will translate the ability of such biomarkers to predict exhaustion into
algorithms that can be incorporated in biosensors. Rigorous validation of such algorithms in
normal as well as diabetic animals will pave the way for human studies. In addition, multi-analyte
monitoring may be applied to study other metabolic diseases such as obesity.

66

Appendix I – Figures
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Figure 2.1. Histological evaluation of the foreign body reaction to control (no dexamethasone)
implants. Star denotes implant location. Connective tissue is stained pink, collagen fibers light
pink and inflammatory cells purple (H&E staining). a: day 1; b: day 3; c: day 7; d: day 14; e: day
21; f: day 30 post-implantation (n=3). Scale bar: 500 μm.
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Figure 2.2. Comparison of FBR in rats and minipigs 7 days post-implantation. Star denotes
implant location. Connective tissue is stained pink, collagen fibers light pink and inflammatory
cells purple (H&E staining). Green arrow: collagen fibers; black arrow: fibroblasts. Rat image
taken from Patil et. al.43 Fibroblasts were identified based on the cell morphology. Active
fibroblasts have oval shape with spherical nucleus and are characteristically positioned in-between
collagen fibers which they produce.
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Figure 2.3. Histological evaluation of the foreign body reaction to dexamethasone-releasing
implants R, R9, R11 and R150 on days 3, 7, 14, 21, and 30 post-implantation. Star denotes implant
location. Connective tissue is stained pink, collagen fibers light pink and inflammatory cells purple
(H&E staining) (n=3). Scale bar: 500 μm.
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Figure 2.4. Histological evaluation of the foreign body reaction to dexamethasone-releasing
implants R2W. Star denotes implant location. Connective tissue is stained pink, collagen fibers
light pink and inflammatory cells purple (H&E staining). a: day 1; b: day 3; c: day 7; d: day 11; e:
day 14; f: day 21 post-implantation (n=4). Scale bar: 500 μm.

71

Figure 3.1. Polarized light microscopy (PLM) images of two emulsions during PLGA microsphere
preparation. Drug crystals appear as bright spots in the PLM images. (a) Example of nonoptimized process, with dexamethasone crystals formed outside the polymer phase (polymer
droplets not visible due to their inability to polarize light). (b) Optimized formulation with
dexamethasone precipitated inside the polymer phase. Magnification: 10X, scale bar: 500 μm.
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Figure 3.2. PLM images of negative control formulation (left) with poor drug distribution in the
polymer matrix and optimized formulation (right). Dexamethasone crystals appear bright under
PLM while the polymer is transparent. Magnification: 40X, scale bars: 10 μm.
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Figure 3.3. Cumulative in vitro release of dexamethasone from optimized PLGA microspheres
embedded in a PVA hydrogels. All values are average ± SD (n = 3). Linear regression was applied
from day 4 to day 45.

74

Figure 3.4. Histological evaluation of the foreign body reaction to control (no dexamethasone)
implants. Star denotes implant location. Connective tissue is stained pink, collagen fibers light
pink and inflammatory cells purple (H&E staining). (a) day 3; (b) day 7; (c) day 14; (d) day 21;
(e) day 30 post-implantation. Magnification: 10X, scale bar: 500 μm.
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Figure 3.5. Histological evaluation of the foreign body reaction to coated silicon chips with the
optimized PLGA microsphere formulation. Star denotes implant location. Connective tissue is
stained pink, collagen fibers light pink and inflammatory cells purple (H&E staining). (a) day 3;
(b) day 7; (c) day 14; (d) day 21; (e) day 30 post-implantation. Magnification: 10X, scale bar: 500
μm.
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Figure 3.6. Histological evaluation of FBR to composites with the optimized PLGA microsphere
formulation with no silicon chips at their core. Star denotes implant location. Connective tissue is
stained pink, collagen fibers light pink and inflammatory cells purple (H&E staining). (a) day 3;
(b) day 7; (c) day 14; (d) day 21; (e) day 30 post-implantation. Magnification: 10X, scale bar: 500
μm.
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Figure 4.1. Schematic representation of the single-vessel microsphere preparation process.
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Figure 4.2. a) Confocal microscopy images of protein microsphere formulations with (right) and
without (left) NaCl in the outer water phase; b) drug loading, encapsulation efficiency, and % burst
release of the formulations with and without NaCl (mean ± SD, n=3).
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Figure 4.3. Anti-sma-stained tissue sections showing normal tissue (N) and composites C, D, DV,
DVP, and D2VPa. Star denotes implant location. Magnification: 20x. Scale bar: 150 μm.
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Figure 4.4. H&E-stained tissue sections of composites D, DV, D2VPb, and 2D2VP at different
time points following implantation. Star denotes implant location. Magnification: 10x. Scale bar:
500 μm.
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Figure 4.5. Anti-sma-stained tissue sections of composites D, DV, D2VPb, and 2D2VP at
different time points following implantation. Star denotes implant location. Magnification: 10x.
Scale bar: 500 μm.
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Figure 4.6. Anti-sma-stained tissue sections of composites D, DV, D2VPb, and 2D2VP at
different time points following implantation. Star denotes implant location. Magnification: 140x.
Scale bar: 100 μm.
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Figure 4.7. Capillary density within a 200 μm distance from the implant surface for composites
D, DV, D2VPb and 2D2VP (mean ± SD, n=3).
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Figure 5.1. Effect of light and intense exercise on oxygen and carbon dioxide levels in the blood
and subcutaneous tissue. Areas shaded blue and green indicate light and intense exercise,
respectively, and unshaded areas indicate periods of inactivity (rest or recovery). The top panel
displays oxygen level changes and the bottom panel carbon dioxide changes in the dialysate.
Arrows indicate y axis. Oxygen levels did not respond to light exercise but only during intense
exercise. Carbon dioxide levels responded to both light and intense exercise, but showed highly
unstable readings.
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Figure 5.2. Effect of intense exercise and exhaustion on glucose and lactate levels in the blood
and subcutaneous tissue. Areas shaded green and red indicate periods of intense exercise and
exhaustion, respectively. Exhaustion was defined as the time when the animal could not keep up
with the exercise and the running speed needed to be adjusted. Unshaded areas indicate periods of
inactivity (rest or recovery). Arrows indicate y axis. Top panels show glucose and lower panels
show lactate changes in the dialysate. Panel a shows representative graph from a normal rat and
panel b from a diabetic rat. Changes in analyte trends precede the onset of exhaustion (red ovals).
These are clearer in lactate trends for both normal and diabetic rats.
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Figure 5.3. Slope changes for various biomarker combinations of glucose (GLU) and lactate
(LAC). All ratios are molar and the percentile changes are calculated based on the baseline
measurements before the commencement of the exercise. The first peak represents metabolic
changes from rest to activity and the second peak metabolic changes that precede exhaustion
(predictive). Panel a shows representative results from a normal rat and panel b from a diabetic
rat.
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Figure 5.4a. Effect of intense exercise and exhaustion on the biomarker 2LAC/GLU (molar ratio
of lactate and glucose multiplied by 2). Areas shaded green and red indicate periods of intense
exercise and exhaustion, respectively. Exhaustion was defined as the time when the animal could
not keep up with the exercise and the running speed needed to be adjusted. Unshaded areas indicate
periods of inactivity (rest or recovery). Arrows indicate y axis. Red ovals indicate the exhaustionprediction point. The top panel shows representative results from a normal rat and the bottom panel
from a diabetic rat. 2LAC/GLU is the optimum biomarker for detecting metabolic changes in the
subcutaneous tissue predictive of imminent exhaustion. The results are less clear in the diabetic
rat; please note that diabetic rats did not receive insulin treatment, and the baseline glucose was
high. This likely interfered with the biomarkers.
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Figure 5.4b. 3D representation of glucose and lactate changes during intense exercise and
exhaustion in a normal rat. This plot reveals the interdependence of glucose and lactate that can be
extrapolated to evaluate the metabolic flexibility (the ability to transition from aerobic to anaerobic
energy utilization). The peak in the graph indicates metabolic changes predictive of exhaustion.
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Table 2.1. Implant composition and size.
Implant

Microspheres

PLGA per ml PVA
solution (mg)

Length
(mm)

Control

Blank

75

7

R

1M

75

7

R150

1M

150

7

R9

1M

75

9

R11

1M

75

11

R2W

2W

150

7
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Table 2.2. Physical properties of PLGA microspheres. Results are average values ± SD (n=3).
Microspheres

Extend of
polymer
degradation

PLGA MW
(g/mol)

Mean particle
size (um ± SD)

Drug loading
(% w/w ± SD)

1M

1 month

25,000

49.18 ± 5.84

10.54 ± 0.34

2W

2 weeks

12,000

38.95 ± 1.94

11.86 ± 0.13
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Table 4.1. Microsphere content in the composites
Microspheres (mg)
per ml PVA solution
Composite
D_MS V_MS
P_MS
VP_MS
C
D
75
DV
75
50
DVP
75
50
50
DV2P
75
25
50
D2VPa
75
50
25
D2VPb
75
50
2DVP
100
50
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Table 4.2. Microsphere characterization
Formulation
Drug Loading
Dexamethasone
VEGF
(% w/w)
(ng/mg)
D_MS
10.54 ± 0.34
V_MS
3.19 ± 0.37
P_MS
VP_MS
3.32 ± 0.17
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PDGF
(ng/mg)
3.86 ± 0.22
1.91 ± 0.16

Particle Size
(μm)
39.63 ± 5.44
33.07 ± 5.46
41.69 ± 7.80
38.37 ± 4.46

